Abstract
Pituitary region tumors, including functional and nonfunctional pituitary adenomas, meningiomas, and craniopharyngiomas, are important and distinct benign entities that have both distinct and shared management issues. It is important to have multidisciplinary management to achieve optimal outcomes for patients with pituitary region tumors. These patients may enjoy normal or near-normal life spans but may have lifelong tumor-related or iatrogenic morbidity that can include visual problems (visual field cuts and gaze palsies), endocrine insufficiencies that require monitoring and replacement, and neurocognitive deficits that impair important capabilities and quality of life.
Because surgical management and medical management may not suffice to prevent morbidity from tumor growth or hormonal secretion, irradiation is an option that must be considered as part of multidisciplinary management. For tumors in this region, fractionated radiation therapy has a long and successful track record in controlling tumor growth and may often be a better choice than radiosurgery.
Radiotherapy’s small daily doses exploit the radiobiological advantages of reoxygenation, redistribution, and repair of DNA damage (which increases the dose that can be given to normal tissues). As most tumors in this location are slow-growing, benign tumors, repopulation of the tumor being irradiated during a course of radiotherapy treatment is not a concern.
Current focused radiation therapy approaches using image guidance and attempting to spare normal tissues such as the hippocampi may result in an improved risk-benefit ratio for patients. Randomized clinical trials to document improved outcomes for patients treated with these advanced technologies or alternative approaches such as proton beam therapy are lacking, as are trials comparing radiosurgery and fractionated radiotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rhoton Jr AL. The anterior and middle cranial base. Neurosurgery. 2002;51:S273–302.
Laws Jr ER, Thapar K. Brain tumors. CA Cancer J Clin. 1993;43:263–71.
Costello RT. Subclinical adenoma of the pituitary gland. Am J Pathol. 1936;12:205–16.
Kernohan JW, Sayre GP. Tumors of the pituitary gland and infundibulum. In: Atlas of tumor pathology. Washington: Armed Forces Institute of Pathology, Section X, Fascicle 36; 1956.
DeMonte F, Al-Mefty O. Meningiomas. In: Kaye AH, Laws ER, editors. Brain tumors. New York: Churchill Livingstone; 1995. p. 675–704.
Moss J, DeCastro R, Patronas NJ, et al. Meningiomas in lymphangioleiomyomatosis. JAMA. 2001;286:1879–81.
Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A. Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK editors. WHO classification of tumours of the central nervous system. 4th ed. Lyon: The International Agency for Research on Cancer; 2007. p. 164–72.
Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997;21:1455–65.
Perry A, Scheithauer BW, Stafford SL, et al. “Malignancy” in meningiomas: a clinicopathologic study of 116 patients. Cancer. 1999;85:2046–56.
Kahn EA, Gosch HH, Seeger JF, et al. Forty-five years experience with the craniopharyngiomas. Surg Neurol. 1973;1:5–12.
Yasargil MG, Curcic M, Kis M, et al. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg. 1990;73:3–11.
Adamson TE, Wiestler OD, Kleihues P, et al. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg. 1990;73:12–7.
Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 1969;16:185–217.
Leavens ME, McCutcheon IF, Samaan NA. Management of pituitary adenomas. Oncology (Williston Park). 1992;6(6):69–79; discussion 79–80.
Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22–39.
Tsang RW, Brierley JD, Panzarella T, et al. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30:557–65.
Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol. 2004;70:183–202.
Perry A. Unmasking the secrets of meningioma: a slow but rewarding journey. Surg Neurol. 2004;61:171–3.
Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary. 2002;5:55–65.
Racine MS, Barkan AL. Medical management of growth hormone-secreting pituitary adenomas. Pituitary. 2002;5:67–76.
Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary. 2002;5:83–8.
Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys. 1993;27:215–21.
Leber KA, Bergloff J, Pendl G. Dose–response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg. 1998;88:43–50.
Stafford SL, Pollock BE, Leavitt JA, et al. A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2003;55:1177–81.
van den Bergh AC, Schoorl MA, Dullaart RP, et al. Lack of radiation optic neuropathy in 72 patients treated for pituitary adenoma. J Neuroophthalmol. 2004;24:200–5.
al-Mefty O, Kersh JE, Routh A, et al. The long-term side effects of radiation therapy for benign brain tumors in adults. J Neurosurg. 1990;73:502–12.
Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56:83–8.
Ohtakara K, Hayashi S, Tanaka H, et al. Clinical comparison of positional accuracy and stability between dedicated versus conventional masks for immobilization in cranial stereotactic radiotherapy using 6-degree-of-freedom image guidance system-integrated platform. Radiother Oncol. 2012;102:198–205.
Marks JE, Baglan RJ, Prassad SC, et al. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys. 1981;7:243–52.
Goldsmith BJ, Larson DA. Conventional radiation therapy for skull base meningiomas. Neurosurg Clin N Am. 2000;11:605–15.
Graham JD, Nahum AE, Brada M. A comparison of techniques for stereotactic radiotherapy by linear accelerator based on 3-dimensional dose distributions. Radiother Oncol. 1991;22:29–35.
Perks JR, Jalali R, Cosgrove VP, et al. Optimization of stereotactically-guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms. Int J Radiat Oncol Biol Phys. 1999;45:507–13.
Taylor BF, Picone J, Kimmett J, et al. Improved hippocampal-sparing using an asymmetric conformal arc technique for treatment of pituitary lesions. Int J Radiat Oncol Biol Phys. 2011;81(Suppl):S291–2.
Kondziolka D, Lunsford LD, Loeffler JS, et al. Radiosurgery and radiotherapy: observations and clarifications. J Neurosurg. 2004;101:585–9.
Boehling NS, Grosshans DR, Bluett JB, et al. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys. 2012;82:643–52.
Arvold ND, Niemierko A, Broussard GP, et al. Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. Int J Radiat Oncol Biol Phys. 2012;83(4):e495–500.
Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf). 1993;38:571–8.
Tsang RW, Brierley JD, Panzarella T, et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol. 1996;41:45–53.
McCord MW, Buatti JM, Fennell EM, et al. Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys. 1997;39:437–44.
Zierhut D, Flentje M, Adolph J, et al. External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys. 1995;33:307–14.
Milker-Zabel S, Debus J, Thilmann C, et al. Fractionated stereotactically guided radiotherapy and radiosurgery in the treatment of functional and nonfunctional adenomas of the pituitary gland. Int J Radiat Oncol Biol Phys. 2001;50:1279–86.
Grabenbauer GG, Fietkau R, Buchfelder M, et al. Hormonally inactive hypophyseal adenomas: the results and late sequelae after surgery and radiotherapy. Strahlenther Onkol. 1996;172:193–7.
Woollons AC, Hunn MK, Rajapakse YR, et al. Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol (Oxf). 2000;53:713–7.
Lillehei KO, Kirschman DL, Kleinschmidt-DeMasters BK, et al. Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery. 1998;43:432–8.
Greenman Y, Ouaknine G, Veshchev I, et al. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol (Oxf). 2003;58:763–9.
Grigsby PW, Simpson JR, Fineberg B. Late regrowth of pituitary adenomas after irradiation and/or surgery. Hazard function analysis. Cancer. 1989;63:1308–12.
Breen P, Flickinger JC, Kondziolka D, et al. Radiotherapy for nonfunctional pituitary adenoma: analysis of long-term tumor control. J Neurosurg. 1998;89:933–8.
Chen Y, Wang CD, Su ZP, et al. Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology. 2012;96(4):333–42.
Park P, Chandler WF, Barkan AL, et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery. 2004;55:100–6.
van den Bergh AC, Hoving MA, Links TP, et al. Radiation optic neuropathy after external beam radiation therapy for acromegaly: report of two cases. Radiother Oncol. 2003;68:101–3.
Goffman TE, Dewan R, Arakaki R, et al. Persistent or recurrent acromegaly. Long-term endocrinologic efficacy and neurologic safety of postsurgical radiation therapy. Cancer. 1992;69:271–5.
Grigsby PW, Stokes S, Marks JE, et al. Prognostic factors and results of radiotherapy alone in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys. 1988;15:1103–10.
Gittoes NJ, Bates AS, Tse W, et al. Radiotherapy for non-function pituitary tumours. Clin Endocrinol (Oxf). 1998;48:331–7.
Sasaki R, Murakami M, Okamoto Y, et al. The efficacy of conventional radiation therapy in the management of pituitary adenoma. Int J Radiat Oncol Biol Phys. 2000;47:1337–45.
Dowsett RJ, Fowble B, Sergott RC, et al. Results of radiotherapy in the treatment of acromegaly: lack of ophthalmologic complications. Int J Radiat Oncol Biol Phys. 1990;19:453–9.
Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141–8.
Gullu S, Keles H, Delibasi T, et al. Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol. 2004;150:465–71.
Giustina A, Bronstein MD, Casanueva FF. Current management practices for acromegaly: an international survey. Pituitary. 2011;14:125–33.
Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:4405–10.
Landolt AM, Haller D, Lomax N, et al. Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab. 2000;85:1287–9.
Roug S, Rasmussen AK, Juhler M, et al. Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit. Eur J Endocrinol. 2010;162:685–94.
Eastman RC, Gorden P, Glatstein E, et al. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992;21:693–712.
Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 2005;62:210–6.
Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000;85:2476–82.
Thalassinos NC, Tsagarakis S, Ioannides G, et al. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly; a long-term follow-up study. Eur J Endocrinol. 1998;138:160–3.
Milker-Zabel S, Zabel A, Huber P, et al. Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma. Int J Radiat Oncol Biol Phys. 2004;59:1088–96.
González B, Vargas G, Espinosa-de-los-Monteros AL, et al. Efficacy and safety of radiotherapy in acromegaly. Arch Med Res. 2011;42:48–52.
Williams M, van Seters AP, Hermans J, et al. Evaluation of the effects of radiotherapy on macroprolactinomas using the decline rate of serum prolactin levels as a dynamic parameter. Clin Oncol (R Coll Radiol). 1994;6:102–9.
Ozgen T, Oruckaptan HH, Ozcan OE, et al. Prolactin secreting pituitary adenomas: analysis of 429 surgically treated patients, effect of adjuvant treatment modalities and review of the literature. Acta Neurochir (Wien). 1999;141:1287–94.
Littley MD, Shalet SM, Reid H, et al. The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas. Q J Med. 1991;81:985–98.
Wallace EA, Holdaway IM. Treatment of macroprolactinomas at Auckland Hospital 1975–91. N Z Med J. 1995;108:50–2.
Tsagarakis S, Grossman A, Plowman PN, et al. Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol (Oxf). 1991;34:399–406.
Sun DQ, Cheng JJ, Frazier JL, Batra S, Wand G, Kleinberg LR, et al. Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev. 2011;34:181–9.
Vicente A, Estrada J, de la Cuerda C, et al. Results of external pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. Acta Endocrinol (Copenh). 1991;125:470–4.
Plowman PN. Pituitary adenoma radiotherapy—when, who and how? Clin Endocrinol (Oxf). 1999;51:265–71.
Becker G, Kocher M, Kortmann RD, et al. Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol. 2002;178:173–86.
Mahmoud-Ahmed AS, Suh JH. Radiation therapy for Cushing’s disease: a review. Pituitary. 2002;5:175–80.
Melby JC. Therapy of Cushing [sic] disease: a consensus for pituitary microsurgery. Ann Intern Med. 1988;109:445–6.
Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing [sic)] disease. A report of 216 cases. Ann Intern Med. 1988;109:487–93.
Howlett TA, Plowman PN, Wass JA, et al. Megavoltage pituitary irradiation in the management of Cushing’s disease and Nelson’s syndrome: long-term follow-up. Clin Endocrinol (Oxf). 1989;31:309–23.
Nagesser SK, van Seters AP, Kievit J, et al. Treatment of pituitary-dependent Cushing’s syndrome: long-term results of unilateral adrenalectomy followed by external pituitary irradiation compared to transsphenoidal pituitary surgery. Clin Endocrinol (Oxf). 2000;52:427–35.
Miller JW, Crapo L. The medical treatment of Cushing’s syndrome. Endocr Rev. 1993;14:443–58.
Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med. 1997;336:172–7.
Selch MT, Ahn E, Laskari A, Lee SP, et al. Stereotactic radiotherapy for treatment of cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys. 2004;59:101–11.
Dufour H, Muracciole X, Metellus P, et al. Long-term tumor control and functional outcome in patients with cavernous sinus meningiomas treated by radiotherapy with or without previous surgery: is there an alternative to aggressive tumor removal? Neurosurgery. 2001;48:285–94.
Milker-Zabel S, Zabel A, Schulz-Ertner D, et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys. 2005;61:809–16.
Jalali R, Loughrey C, Baumert B, et al. High precision focused irradiation in the form of fractionated stereotactic conformal radiotherapy (SCRT) for benign meningiomas predominantly in the skull base location. Clin Oncol (R Coll Radiol). 2002;14:103–9.
Debus J, Wuendrich M, Pirzkall A, et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol. 2001;19:3547–53.
Uy NW, Woo SY, Teh BS, et al. Intensity-modulated radiation therapy (IMRT) for meningioma. Int J Radiat Oncol Biol Phys. 2002;53:1265–70.
Hetelekidis S, Barnes PD, Tao ML, et al. 20-year experience in childhood craniopharyngioma. Int J Radiat Oncol Biol Phys. 1993;27(2):189–95.
Kalapurakal JA. Radiation therapy in the management of pediatric craniopharyngiomas—a review. Childs Nerv Syst. 2005;21(8–9):808–16.
Schoenfeld A, Pekmezci M, Barnes MJ, et al. The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. J Neurooncol. 2012;108:133–9.
Hasegawa T, Kondziolka D, Hadjipanayis CG, et al. Management of cystic craniopharyngiomas with phosphorus-32 intracavitary irradiation. Neurosurgery. 2004;54:813–20.
Glod J, Koch B, Myseros J, Breneman J, et al. Issues concerning the treatment of a child with a craniopharyngioma. Med Pediatr Oncol. 2002;38:360–7.
Freeman CR, Patrocinio H, Farmer JP. Highly conformal radiotherapy for craniopharyngioma: (potentially) throwing the baby out with the bathwater. Med Pediatr Oncol. 2003;40:340–1.
Selch MT, DeSalles AA, Wade M, et al. Initial clinical results of stereotactic radiotherapy for the treatment of craniopharyngiomas. Technol Cancer Res Treat. 2002;1:51–9.
Combs SE, Thilmann C, Huber PE, et al. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer. 2007;109:2308–14.
Minniti G, Saran F, Traish D, et al. Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol. 2007;82:90–5.
Smee RI, Williams JR, Kwok B, et al. Modern radiotherapy approaches in the management of craniopharyngiomas. J Clin Neurosci. 2011;18:613–7.
Masson-Cote L, Masucci GL, Atenafu EG, et al. Long-term outcomes for adult craniopharyngioma following radiation therapy. Acta Oncol. 2013;52(1):153–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Knisely, J.P.S., Sperduto, P.W. (2015). Pituitary and Pituitary Region Tumors: Viewpoint—Fractionated Radiation Therapy. In: Chin, L., Regine, W. (eds) Principles and Practice of Stereotactic Radiosurgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8363-2_28
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8363-2_28
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8362-5
Online ISBN: 978-1-4614-8363-2
eBook Packages: MedicineMedicine (R0)